OncoMatch/Clinical Trials/NCT06180733
Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer
Is NCT06180733 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Pembrolizumab for endometrial cancer.
Treatment: Pembrolizumab — The goal of this clinical trial is to establish the fraction of patients that achieve a major pathological response (MPR) after 9 cycles of pembrolizumab, with the ultimate aim of informing a follow-up randomized trial. Participants will receive 9 cycles of pembrolizumab before their standard of care hysterectomy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Endometrial Cancer
Biomarker criteria
Required: MMR deficient
G3/CC MMRd uterine cancer
Disease stage
Grade: G3
histologically confirmed primary diagnosis of G3/CC MMRd uterine cancer
Prior therapy
Cannot have received: anti-PD-1/PD-L1/PD-L2 or co-inhibitory T-cell receptor therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
Cannot have received: systemic anti-cancer therapy
Exception: within 4 weeks prior to allocation
Has received prior systemic anti-cancer therapy including investigational agents within 4 weeks [could consider shorter interval for kinase inhibitors or other short half-life drugs] prior to allocation.
Cannot have received: radiotherapy
Exception: within 2 weeks of start of study treatment or radiation-related toxicities requiring corticosteroids. Note: Two weeks or fewer of palliative radiotherapy for non-CNS disease with a 1-week washout is permitted.
Has received prior radiotherapy within 2 weeks of start of study treatment or radiation-related toxicities requiring corticosteroids.
Cannot have received: investigational agent/device
Exception: within 4 weeks prior to study intervention administration
Has received an investigational agent or has used an investigational device within 4 weeks prior to study intervention administration.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify